Darunavir, cobicistat, emtricitabine, and tenofovir alafenamide (Oral)
Medically reviewed by Drugs.com. Last updated on May 22, 2022.
Warning: Post treatment acute exacerbation of hepatitis BSevere acute exacerbations of hepatitis B (HBV) have been reported in patients who are coinfected with HIV-1 and HBV and have discontinued products containing emtricitabine and/or tenofovir disoproxil fumarate (TDF), and may occur with discontinuation of darunavir/cobicistat/emtricitabine/tenofovir alafenamide. Closely monitor hepatic function with both clinical and laboratory follow-up for at least several months in patients who are coinfected with HIV-1 and HBV and discontinue darunavir/cobicistat/emtricitabine/tenofovir alafenamide. If appropriate, anti-hepatitis B therapy may be warranted .
Commonly used brand name(s)
In the U.S.
- Symtuza
Available Dosage Forms:
- Tablet
Therapeutic Class: Antiretroviral Agent
Pharmacologic Class: Protease Inhibitor
Uses for darunavir, cobicistat, emtricitabine, and tenofovir alafenamide
Darunavir, cobicistat, emtricitabine, and tenofovir alafenamide combination is used to treat human immunodeficiency virus (HIV) infection. HIV is the virus that causes acquired immune deficiency syndrome (AIDS). Darunavir, cobicistat, emtricitabine, and tenofovir alafenamide is usually given to patients who have yet not received any medicine for HIV infection.
Darunavir, cobicistat, emtricitabine, and tenofovir alafenamide combination will not cure or prevent HIV infection or AIDS. It helps keep HIV from reproducing and appears to slow down the destruction of the immune system. This may help delay problems that are usually related to AIDS or HIV disease from occurring. Darunavir, cobicistat, emtricitabine, and tenofovir alafenamide will not keep you from spreading HIV to other people. People who receive darunavir, cobicistat, emtricitabine, and tenofovir alafenamide may continue to have other problems usually related to AIDS or HIV disease.
Darunavir, cobicistat, emtricitabine, and tenofovir alafenamide is available only with your doctor's prescription.
Before using darunavir, cobicistat, emtricitabine, and tenofovir alafenamide
In deciding to use a medicine, the risks of taking the medicine must be weighed against the good it will do. This is a decision you and your doctor will make. For darunavir, cobicistat, emtricitabine, and tenofovir alafenamide, the following should be considered:
Allergies
Tell your doctor if you have ever had any unusual or allergic reaction to darunavir, cobicistat, emtricitabine, and tenofovir alafenamide or any other medicines. Also tell your health care professional if you have any other types of allergies, such as to foods, dyes, preservatives, or animals. For non-prescription products, read the label or package ingredients carefully.
Pediatric
Appropriate studies performed to date have not demonstrated pediatric-specific problems that would limit the usefulness of darunavir, cobicistat, emtricitabine, and tenofovir alafenamide combination in children weighing at least 40 kilograms (kg). Safety and efficacy have not been established in children weighing less than 40 kg.
Geriatric
Appropriate studies performed to date have not demonstrated geriatric-specific problems th..
